REGN Stock Recent News

European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.

Regeneron's Eylea franchise remains resilient despite biosimilar competition, with Eylea HD showing strong performance and new innovations like a pre-filled syringe on the horizon. Dupixent continues to drive growth, especially with the addition of COPD to its label, and is expected to generate significant future revenue. Libtayo shows robust growth in specific cancers, although it faces stiff competition in broader indications, highlighting Regeneron's ability to develop blockbuster drugs.

Three stocks which have generated 100-bagger returns for investors over the past 20 years are Booking Holdings (BKNG -3.58%), Apple (AAPL -7.28%), and Regeneron Pharmaceuticals (REGN -6.11%). Here's a look at how much a $1,000 investment into each of these stocks back then would be worth now, and whether it's still a good idea to invest in them.

Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.

Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., fixing the health care industry, and more.